- Home
- ICUI vs WGSWW Comparison
ICUI vs WGSWW Comparison
Compare ICUI & WGSWW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICUI
- WGSWW
- Stock Information
- Founded
- ICUI 1984
- WGSWW N/A
- Country
- ICUI United States
- WGSWW United States
- Employees
- ICUI N/A
- WGSWW 1000
- Industry
- ICUI Medical/Dental Instruments
- WGSWW Retail: Computer Software & Peripheral Equipment
- Sector
- ICUI Health Care
- WGSWW Technology
- Exchange
- ICUI Nasdaq
- WGSWW Nasdaq
- Market Cap
- ICUI N/A
- WGSWW N/A
- IPO Year
- ICUI 1992
- WGSWW 2020
- Fundamental
- Price
- ICUI $168.84
- WGSWW $0.17
- Analyst Decision
- ICUI Buy
- WGSWW
- Analyst Count
- ICUI 5
- WGSWW 0
- Target Price
- ICUI $173.00
- WGSWW N/A
- AVG Volume (30 Days)
- ICUI 241.1K
- WGSWW N/A
- Earning Date
- ICUI 11-12-2024
- WGSWW N/A
- Dividend Yield
- ICUI N/A
- WGSWW N/A
- EPS Growth
- ICUI N/A
- WGSWW N/A
- EPS
- ICUI N/A
- WGSWW N/A
- Revenue
- ICUI $2,340,097,000.00
- WGSWW N/A
- Revenue This Year
- ICUI $4.42
- WGSWW N/A
- Revenue Next Year
- ICUI $4.03
- WGSWW N/A
- P/E Ratio
- ICUI N/A
- WGSWW N/A
- Revenue Growth
- ICUI 4.04
- WGSWW N/A
- 52 Week Low
- ICUI $83.26
- WGSWW N/A
- 52 Week High
- ICUI $196.26
- WGSWW N/A
- Technical
- Relative Strength Index (RSI)
- ICUI 41.05
- WGSWW N/A
- Support Level
- ICUI $164.25
- WGSWW N/A
- Resistance Level
- ICUI $174.79
- WGSWW N/A
- Average True Range (ATR)
- ICUI 6.56
- WGSWW 0.00
- MACD
- ICUI -0.91
- WGSWW 0.00
- Stochastic Oscillator
- ICUI 19.61
- WGSWW 0.00
About WGSWW GeneDx Holdings Corp.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets. It has two segments GeneDx, which derives maximum revenue and Legacy Sema4 diagnostics.